Unadjusted all-cause direct costs for patients with AS and PsA: 12-month followup.
| Resource Use | AS, n = 4288 | PsA, n = 10,832 | ||
|---|---|---|---|---|
| Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | |
| Medical costs, US$* | ||||
| Hospitalizations | $4185 ($26,503) | $0 (0) | $3064 ($17,444) | $0 (0) |
| ER visits | $758 ($4237) | $0 (0) | $586 ($2717) | $0 (0) |
| Office visits | $1571 ($2242) | $1008 ($1183) | $1458 ($2097) | $1020 ($1024) |
| Prescription drug costs, US$† | ||||
| Biologics use | $11,162 ($14,021) | $3016 ($22,690) | $14,061 ($15,593) | $12,541 ($24,446) |
| nbDMARD use | $52 ($228) | $0 (0) | $113 ($228) | $12 ($143) |
↵* Medical costs were calculated as hospitalization costs plus ER and office visit costs in US dollars.
↵† Prescription drug costs were calculated as biologics plus oral drug costs in US dollars. AS: ankylosing spondylitis; PsA: psoriatic arthritis; IQR: interquartile range; ER: emergency room; nbDMARD: nonbiologic disease-modifying antirheumatic drug.